Products - Colorectal cancer | Topic | NICE

Showing 5 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
25 February 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2026
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC